+

Realizing individualized cancer treatment through patient genome sequencing

Recent Publications

Ogawa, A., Izumikawa, K., Tate, S., Isoyama, S., Mori, M., Fujiwara, K., Watanabe, S., Ohga, T., Jo, U., Taniyama, D., Kitajima, S., Tanaka, S., Onji, H., Kageyama, S.-I., Yamamoto, G., Saito, H., Morita, T. Y., Okada, M., Natsumeda, M., Nagahama, M., Kobayashi, J., Ohashi, A., Sasanuma, H., Higashiyama, S., Dan, S., Pommier, Y. and Murai, J.
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis.
Mol. Cell, in press (2025)
Utsumi, T., Mizuta, H., Seto, Y., Uchibori, K., Nishio, M., Okamoto, I. and Katayama, R.
AXL-mediated drug resistance in ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11 positive fibroblasts.
Cancer Sci., in press (2025)
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N. and Katayama, R.
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.
npj Precis Oncol, in press (2025)
Sasaki, N., Homme, M., Murayama, T., Osaki, T., Tenma, T., An, T., Takegami, Y., Tani, T., Gedeon, P. C., Kobayashi, Y., Cañadas, I., Barbie, D. A., Yao, R. and Kitajima, S.
RNA sensing induced by chromosome missegregation augments anti-tumor immunity.
Mol. Cell, in press (2024)
Fujimura, T., Furugaki, K., Mizuta, H., Muraoka, S., Nishio, M., Adachi, J., Uchibori, K., Miyauchi, E., Hayashi, H., Katayama, R. and Yoshiura, S.
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.
NPJ Precis. Oncol., 264, in press (2024)

more

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载